Anti‐angiogenic and vascular disrupting effects of C9, a new microtubule‐depolymerizing agent
- 6 April 2009
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 156 (8), 1228-1238
- https://doi.org/10.1111/j.1476-5381.2009.00112.x
Abstract
The critical role of blood supply in the growth of solid tumours makes blood vessels an ideal target for anti-tumour drug discovery. The anti-angiogenic and vascular disrupting activities of C9, a newly synthesized microtubule-depolymerizing agent, were investigated with several in vitro and in vivo models. Possible mechanisms involved in its activity were also assessed. Microtubule-depolymerizing actions were assessed by surface plasmon resonance binding, competitive inhibition and cytoskeleton immunofluorescence. Anti-angiogenic and vascular disrupting activities were tested on proliferation, migration, tube formation with human umbilical vein endothelial cells, and in rat aortic ring, chick chorioallantoic membrane and Matrigel plug assays. Western blots and Rho activation assays were employed to examine the role of Raf-MEK-ERK (mitogen-activated ERK kinase, extracellular signal-regulated kinase) and Rho/Rho kinase signalling. C9 inhibited proliferation, migration and tube formation of endothelial cells and inhibited angiogenesis in aortic ring and chick chorioallantoic membrane assays. C9 induced disassembly of microtubules in endothelial cells and down-regulated Raf-MEK-ERK signalling activated by pro-angiogenic factors. In addition, C9 disrupted capillary-like networks and newly formed vessels in vitro and rapidly decreased perfusion of neovasculature in vivo. Endothelial cell contraction and membrane blebbing induced by C9 in neovasculature was dependent on the Rho/Rho kinase pathway. Anti-angiogenic and vascular disruption by C9 was associated with changes in morphology and function of endothelial cells, involving the Raf-MEK-ERK and Rho/Rho kinase signalling pathways. These findings strongly suggest that C9 is a new microtubule-binding agent that could effectively target tumour vasculature.This publication has 39 references indexed in Scilit:
- Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effectEuropean Journal of Pharmacology, 2004
- Antimitotic Antifungal Compound Benomyl Inhibits Brain Microtubule Polymerization and Dynamics and Cancer Cell Proliferation at Mitosis, by Binding to a Novel Site in TubulinBiochemistry, 2004
- Vascular Targeting Agents as Cancer TherapeuticsClinical Cancer Research, 2004
- Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJCI Insight, 2003
- Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.2003
- 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIFCancer Cell, 2003
- The tumor vascular targeting agent combretastatin A–4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cellsBlood, 2002
- The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-AngiogenesisCurrent Pharmaceutical Biotechnology, 2000
- Culture of Human Endothelial Cells Derived from Umbilical Veins. IDENTIFICATION BY MORPHOLOGIC AND IMMUNOLOGIC CRITERIAJCI Insight, 1973
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971